They get a type of lung cancer that's often called an adenocarcinoma.

他们得的是一通常被称为腺癌的肺癌。

Most frequently, adenocarcinoma develops as a consequence of gastroesophageal reflux disease, or GERD for short.

最常见的一是胃食管反流（简称GERD）导致食管腺癌。

Barrett's esophagus poses a higher risk of developing esophageal adenocarcinoma.

Barrett食管患者发生食管腺癌的风险较高。

The strongest risk factor for adenocarcinoma, on the other hand, is chronic GERD and Barrett's esophagus.

另一方面，腺癌最强的危险因素是慢性胃食管反流病与Barrett食管。

So, adenocarcinoma arises from columnar glandular epithelium.

腺癌来源柱状上皮腺体细胞。

However, if the cells look abnormal, that's called dysplasia, and there's a higher risk of developing adenocarcinoma.

然而，如果这些细胞看起来异常，那就叫做异型增生，并且发生腺癌的风险更高。

Obesity and being a genetically male individual also increase the risk of adenocarcinoma.

肥胖与性别为男性，也会增加罹患腺癌风险。

And I think the overall effect was like three or 400% increased risk of adenocarcinoma.

我认为总体影响是腺癌风险增加 300％ 或 400％。

I remember reading a meta-analysis of the effect of smoking on the risk of adenocarcinoma, right?

我记得读过一篇烟对腺癌风险影响的荟萃分析，对吗？

The FDA has approved capmatinib in this subset of lung adenocarcinomas.

FDA 已批准卡马替尼用治疗这一肺腺癌。

BRAF mutations BRAF mutations are observed in 1-2% of lung adenocarcinomas.

BRAF 突变 1-2% 的肺腺癌中观察到 BRAF 突变。

However, adenocarcinoma is the most common cause of GGO, and careful evaluation for pulmonary malignancy must be considered when GGO is identified.

然而，腺癌是 GGO 最常见的原因，当发现 GGO 时， 必须考虑仔细评估肺部恶性肿瘤。

Non-small-cell lung cancer (NSCLC), which includes adenocarcinoma, squamous cell carcinoma and large cell carcinoma, accounts for 80- 85% of all lung cancers.

非小细胞肺癌（NSCLC）包括腺癌、鳞状细胞癌和大细胞癌，占所有肺癌的80-85%。

The prevalence of HER2 overexpression is 2.4- 38%, mainly in adenocarcinoma.

HER2过表达的患病率为2.4-38%，主要见腺癌。

Most targetable mutations occur in the adenocarcinoma subtype of NSCLC.

大多数靶向突变发生在 NSCLC 的腺癌亚型中。

This is called Barrett's esophagus - or Barrett's metaplasia, and the cylindrical epithelium has a greater risk of degenerating into a particular type of esophageal cancer, called adenocarcinoma.

这被称为Barrett食管或Barrett生，而柱状上皮有更大的风险退为一特殊类型的食管癌，称为腺癌。

Patients with adenocarcinoma should have genomic testing for EGFR, ALK, ROS1, KRAS, NTRK, BRAF, RET, MET, HER2 (ERBB2) and NRG1 at diagnosis.

腺癌患者在诊断时应进行 EGFR、ALK、ROS1、KRAS、NTRK、BRAF、RET、MET、HER2 (ERBB2) 和 NRG1 基因组检测。

Well-differentiated tumors with adenocarcinoma or squamous cell carcinoma morphology can be diagnosed by routine light microscopy, without the need for IHC.

具有腺癌或鳞状细胞癌形态的分良好的肿瘤可以通过常规光学显微镜进行诊断，而不需要 IHC。

Sub-solid nodules will require longer follow-up than solid nodules as they may represent premalignant adenocarcinoma in situ or minimally invasive adenocarcinoma.

亚实性结节比实性结节需要更长的随访时间，因为它们可能代表癌前原位腺癌或微浸润腺癌。

NOS carcinomas that stain with adenocarcinoma markers are classifed as 'NSCLC, favor adenocarcinoma'; tumors that stain with squamous markers are classified as 'NSCLC, favor squamous cell carcinoma'.

带有腺癌标志物染色的 NOS 癌被归类为“NSCLC，有利腺癌”；用鳞状细胞标记染色的肿瘤被归类为“非小细胞肺癌，有利鳞状细胞癌”。